FDA Webinar: Safety Assessment of Genome Editing in Gene Therapy
Food and Drug Administration, Office of Therapeutics Products · June 23, 2026
FDA presenter Komudi Singh outlined a newly published draft guidance recommending how developers should use next-generation sequencing (NGS) in nonclinical safety assessments of human genome‑editing products, and invited public feedback at the docket.
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.
No transcript available.
No outline available for this source.
No related articles available for this source.
No highlights available for this source.
No claims available for this source.
No actions available for this source.
No topics available for this source.
No clarifying details available for this source.
No discussions available for this source.
No community relevance data available for this source.
No funding sources available for this source.
No speakers available for this source.
No transcript available for this source.